NCT03257761 2025-12-05
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT02998567 2025-08-17
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT01966289 2021-03-30
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02293993 2021-03-05
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Otsuka Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02429466 2020-09-23
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Indiana University
Phase 1 Completed
NCT02892318 2020-03-13
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Hoffmann-La Roche
Phase 1 Completed
NCT03085849 2018-12-10
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Columbia University
Phase 1 Completed
NCT02608437 2015-11-18
NIBIT-M4
Italian Network for Tumor Biotherapy Foundation
Phase 1 Unknown